

Therapeutic approaches and pharmaceutical compositions are claimed, as are research uses, and are available for licensing.

Delayed Progression to AIDS by a Missense Allele of the CCR2 Gene

M Dean, SJ O'Brien, M Carrington, MW Smith (NCI)

DHHS Reference No. E-209-97/0 filed 14 Aug 97

A specific variant of chemokine receptor CCR2, which appears to be a co-receptor for HIV-1, has been identified. This variant, CCR2-64I, is associated with delayed progression to AIDS in individuals infected with HIV-1, and is the result of a conservative amino acid substitution within the first transmembrane receptor region of CCR2. CCR2-64I is independent of but additive with CCR5-d32, an allele of chemokine receptor CCR5 which is also associated with delayed progression to AIDS. Together, these two polymorphisms are present in nearly 40% of individuals in all ethnic groups; CCR2-64I alone occurs at an allele frequency of 10-29% in all ethnic groups. Polynucleotides and polypeptides are provided by the invention. Therapeutic approaches and pharmaceutical compositions are claimed, as are research uses, diagnostic uses, and screening methods.

CC Chemokine Receptor 8 DNA, New Animal Models And Therapeutic Agents For HIV Infection

HL Tiffany, PM Murphy, G Alkhatib, EA Berger (NIAID)

DHHS Reference No. E-220-97/0 filed 29 July 97

CCR8, a known chemokine receptor, has now been shown to serve as a co-receptor for HIV-1. This receptor, a seven transmembrane region G protein coupled receptor, binds chemokine I-309, which is a potent monocyte attractant and is capable of inhibiting apoptosis in thymic cell lines. CCR8 is expressed in both monocytes and thymus, and is encoded by a gene of previously unknown function. Polynucleotides and polypeptides are provided by the invention. Therapeutic approaches and pharmaceutical compositions are claimed, as are research uses.

Functional Promoter For CCR5

F Guignard (NIAID)

DHHS Reference No. E-222-97/0

Embodied in this invention is the identification of the functional promoter sequence for CCR5. CCR5 is a known

chemokine receptor which functions as a cofactor for HIV binding and is found on the cell surface of macrophages and CD4+ T cells. Blocking or suppressing the expression of CCR5 may therefore serve to inhibit HIV infection. It is postulated that this could be accomplished by inhibiting the CCR5 promoter or by administering an oligonucleotide analog of the promoter, thereby treating or preventing HIV infection. Polynucleotide sequences are provided by the invention. Therapeutic approaches and pharmaceutical compositions are claimed, as are research uses.

CCR1 Knockout Mouse

J-L Gao, PM Murphy (NIAID)

DHHS Reference No. E-234-97/0

Embodied in this invention is a CC chemokine receptor 1 (CCR1) knockout mouse, which has been made deficient (-/-) by targeted gene disruption. CCR1 normally binds chemokines MIP-1a and RANTES. The inventors have already used these knockout mice to identify a number of biological functions for CCR1, which are described in Gao et al., *The Journal of Experimental Medicine* 185(11): 1959-1968, June 1997. The mice are available for licensing via a Biological Materials License, and numerous research uses are anticipated.

Dated: March 9, 1998.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 98-6892 Filed 3-16-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Center for Research Resources Special Emphasis Panel (SEP) meeting:

Name of SEP: Biomedical Research Technology (Telephone Conference Call).

Date: April 1, 1998.

Time: 10:00 a.m.

Place: National Institutes of Health, 6507 Rockledge Drive, MSC 7965, Room 6018, Bethesda, MD 20892-7965.

Contact Person: Dr. Raymond R. O'Neill, Scientific Review Administrator, 6705 Rockledge Drive, MSC 7965, Room 6018, Bethesda, MD 20892-7965, (301) 435-0820.

Purpose/Agenda: To evaluate and review grant applications.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.371, Biomedical Research Technology, National Institutes of Health, HHS)

Dated: March 5, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-6790 Filed 3-16-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Center for Research Resources Special Emphasis Panel (SEP) meetings:

Name of SEP: Biomedical Research Technology.

Date: March 23-25, 1998.

Time: March 23, 6:00 p.m.-10:00 p.m.; March 24, 8:00 a.m.-6:30 p.m.; March 25, 8:00 a.m.-2:00 p.m.

Place: Doubletree Hotel, 1750 Rockville Pike, Rockville, MD 20852, (301) 468-1100.

Contact Person: Dr. Bela J. Gulyas, Scientific Review Administrator, 6705 Rockledge Drive, MSC 7965, Room 6018, Bethesda, MD 20892-7965, (301) 435-0811.

Purpose/Agenda: To evaluate and review grant applications.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.371, Biomedical Research, National Institutes of Health, HHS)